The European Medicines Agency (EMA) asserts that AstraZeneca’s COVID vaccine is safe and effective. “The benefits,” said director Emer Cooke, “outweigh the risks. The vaccine does not present a risk of thrombosis.”
According to EMA’s clinical committee, the vaccine “cannot be associated with an increase in thrombotic events,” specified Emer Cooke.
The agency did not deny the existence of adverse cases and indeed announced that it would continue to investigate: “We will launch new investigations to better understand,” said the director of the agency. On the other hand, cases of thrombosis after the administration of the AstraZeneca vaccine are “lower” than those occurring in the unvaccinated population, explains Sabien Straus, chair of the PRAC (Pharmacovigilance Risk Assessment Committee).
“The benefits of AstraZeneca’s vaccine continue to outweigh the risks. The EMA’s safety committee found no evidence of quality issues or batches,” continued Sabine Strauss.
